CME

Faculty: Luis Paz-Ares, MD, PhD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Luis Paz-Ares, MD, PhD Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Par...

Faculty: Lauren A. Byers, MD This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical in...

Host: Joseph F. Goldberg, MD Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.

Faculty: Javed Butler, MD, MPH, MBA Faculty: James Burton, DM, FRCP Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antago...

Faculty: James Burton, DM, FRCP Faculty: Patrick Rossignol, MD, PhD Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antago...

Faculty: James Burton, DM, FRCP Faculty: Ellie Kelepouris, MD, FACP, FAHA Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Javed Butler, MD, MPH, MBA Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid recep...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Patrick Rossignol, MD, PhD Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid recep...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Patrick Rossignol, MD, PhD Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid recep...

Faculty: James Burton, DM, FRCP Faculty: Javed Butler, MD, MPH, MBA Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antago...

Faculty: Shikha Wadhwani, MD Faculty: Dana Rizk, MD For the second episode of the KDIGO IgA Nephropathy (IgAN) podcast series, Dr. Dana Rizk and Dr. Shikha Wadhwani discuss the IgAN treatment revolution. The conversation explores how a deeper understanding of the disease's pathophysiology has led to new therapeutic options, moving beyond traditional supportive care. Key topics include: The shift i...

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Javed Butler, MD, MPH, MBA Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid recep...

Guest: James Burton, DM, FRCP Guest: Javed Butler, MD Guest: Ellie Kelepouris, MD, FACP, FAHA Guest: Patrick Rossignol, MD, PhD Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone sys...

Host: Christopher J. Richards, MD Host: Ashley Losier, MD Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. Thi...

Faculty: Marion Munk, MD, Ph. D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: David Boyer, MD Faculty: Marion Munk, MD, Ph. D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Diana V. Do, MD Faculty: Marion Munk, MD, Ph. D This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Marion Munk, MD, Ph. D Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Marion Munk, MD, Ph. D Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patien...

Faculty: Diana V. Do, MD Faculty: David Boyer, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may...

Faculty: David Boyer, MD Faculty: Diana V. Do, MD This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may...

Guest: Janis T. Eells, Ph. D. This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, an...

Host: Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM Guest: Daniel C. Butler, MD Guest: Benjamin Ungar, MD On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.